New EU Filings
A Regularly Updated List Of New Marketing Authorization Applications At The EMA
Executive Summary
BioMarin Pharmaceutical's investigational gene therapy, Roctavian (valoctocogene roxaparvovec), for treating adults with severe hemophilia A is among the latest new medicines that have been submitted for pan-EU approval.
You may also be interested in...
Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings
Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.